Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01781611 · ClinicalTrials.gov registry record · NA
Dipyridamole Assessment for Flare Reduction in Systemic Lupus Erythematosus (SLE)
A NA study, sponsored by Oklahoma Medical Research Foundation.
- Terminated
- Registry status
- NA
- Development phase
- 18
- Enrollment target
NCT01781611 is a NA study that was terminated before completion, run by Oklahoma Medical Research Foundation. The registered enrollment target is 18 participants.
The verdict
NCT01781611, a NA study, was terminated before completion, sponsored by Oklahoma Medical Research Foundation.
- TERMINATED
- Registry status
- NA
- Development phase
- 18 participants
- Enrollment target
Study Summary
Dipyridamole, a medication extensively used in combination with aspirin for stroke prevention, is a promising new treatment for lupus. Dipyridamole has been shown to inhibit certain lymphocyte populations that are over-reactive in lupus and to delay the emergence of lupus-related pathology in mice with lupus. The investigators are interested in investigating the efficacy of dipyridamole in preventing flares in patients with lupus and its impact on biomarkers of disease activity.
Interventions
- DRUG extended release dipyridamole 200mg/aspirin 25mg
- DRUG 81mg aspirin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2013-02 |
| Est. Completion | 2017-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01781611
The ClinicalTrials.gov registry entry for NCT01781611 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oklahoma Medical Research Foundation, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which extended release dipyridamole 200mg/aspirin 25mg is the first listed.
NCT01781611 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01781611 about?
NCT01781611 is a clinical study titled "Dipyridamole Assessment for Flare Reduction in Systemic Lupus Erythematosus (SLE)". Dipyridamole, a medication extensively used in combination with aspirin for stroke prevention, is a promising new treatment for lupus. Dipyridamole has been shown to inhibit certain lymphocyte populations that are over-reactive in lupus and to delay the emergence of lupus-related pathology in mice w...
What is the current status of trial NCT01781611?
This trial is currently terminated. It is a NA study. The enrollment target is 18 participants. The study started on 2013-02. Estimated completion is 2017-11.
What interventions are being tested in trial NCT01781611?
The interventions under investigation include: extended release dipyridamole 200mg/aspirin 25mg (DRUG), 81mg aspirin (DRUG).
Who is sponsoring clinical trial NCT01781611?
This trial is sponsored by Oklahoma Medical Research Foundation, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.